Switch to Sylvia Ng's research page...

2008

1. Baker JHE, Lam J, Kyle AH, Sy J, Oliver T, Co S, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SSW, Bally MB and Yapp DTT (2008). Irinophore C^TM, A Novel Nano-Formulation of Irinotecan, Alters Tumor Vascular Function, and Enhances the Distribution of 5-FU and Doxorubicin Clin Cancer Res 2008 Nov 15:14(22):7260-7l (2008).
    [View Abstract - PubMed 19010842]  Request Paper

2006

2. Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS. Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin Cancer Res. 12(14):4331-8. (2006).
    [View Abstract - PubMed 16857808]  Request Paper

2004

3. Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem. 47(9):2219-27. (2004).
    [View Abstract - PubMed 15084120]  Request Paper

4. McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother. 27(2):161-75. (2004).
    [View Abstract - PubMed 14770088]  Request Paper

5. Ng SS, Figg WD. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biol Ther. 3(12):1212-3. Epub 2004 Dec 15. (2004).
    [View Abstract - PubMed 15662130]  Request Paper

6. Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 64(3):821-4. (2004).
    [View Abstract - PubMed 14871806]  Request Paper

7. Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res. 10(12 Pt 1):4192-7. (2004).
    [View Abstract - PubMed 15217957]  Request Paper

8. Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker C, Zeldis J, Figg WD. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer. 2(4):241-3. (2004).
    [View Abstract - PubMed 15072608]  Request Paper

2003

9. Luzzio FA, Mayorov AV, Ng SS, Kruger EA, Figg WD. Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. J Med Chem. 46(18):3793-9. (2003).
    [View Abstract - PubMed 12930142]  Request Paper

10. Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther. 2(9):845-54. (2003).
     [View Abstract - PubMed 14555703]  Request Paper

11. Ng SS, Figg WD. Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. Anticancer Res. 23(5A):3585-90. (2003).
     [View Abstract - PubMed 14666653]  Request Paper

12. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK, Luzzio FA, Kruger EA, Eger K, Figg WD. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. 63(12):3189-94. (2003).
     [View Abstract - PubMed 12810647]  Request Paper

2002

13. Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, Figg WD. Antiangiogenesis therapeutic strategies in prostate cancer. Cancer Metastasis Rev. 21(1):93-106. (2002).
     [View Abstract - PubMed 12400998]  Request Paper

14. Ng SS, Brown M, Figg WD. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed Pharmacother. 56(4):194-9. (2002).
     [View Abstract - PubMed 12109812]  Request Paper

15. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 1(10):777-83. (2002).
     [View Abstract - PubMed 12492110]  Request Paper

2001

16. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 7(10):3269-75. (2001).
     [View Abstract - PubMed 11595724]  Request Paper

2000

17. Ng SS, Pang CC. In vivo venodilator action of fenoldopam, a dopamine D(1)-receptor agonist. Br J Pharmacol. 129(5):853-8. (2000).
     [View Abstract - PubMed 10696081]  Request Paper

18. Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60(19):5451-5. (2000).
     [View Abstract - PubMed 11034087]  Request Paper

2008

1. Syliva S.W. Ng and Kim N. Chi. Chapter 27: Surrogates for Clinical Development In: Angiogenesis: An integrated approach from science to medicine (2008).
    Request Paper

2002

2. Macpherson, G.R., Ng, S.S.W., Lakhani, N.J., Price, D.K., Venitz, J. and Figg, W.D. . Antiangiogenesis therapeutic strategies in prostate cancer. In Cher, M.L. and Raz., A. (eds), Prostate Cancer: New Horizons in Research and Treatment, 317-330. Kluwer Academic Publishers, the Netherlands. (2002).
    Request Paper